ArticleCirculation2018
Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction.
Open access · hybridAbstract read
In one paragraph
Article in Circulation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Mesenchymal Stem Cell Exosomes in the Treatment of Myocardial Infarction: a Systematic Review of Preclinical In Vivo Studies.Journal of cardiovascular translational research · 2022Pooled it
- SOX2-OT serves as a diagnostic and prognostic biomarker for hypertensive left ventricular hypertrophy by targeting miR-30d-5p.Molecular and cellular biochemistry · 2026Article
- Targeting Runx1 Slows Cyst Growth in Autosomal Dominant Polycystic Kidney Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Article
- Targeting RUNX1 protects against diastolic dysfunction in a two-hit mouse model of heart failure with preserved ejection fraction.Cardiovascular research · 2026Article
- ETS‑1/ETS‑2 transcription factors in CVD (Review).International journal of molecular medicine · 2026Review
- Exercise-primed exosomes in an injectable hydrogel promote myocardial repair via angiogenesis and ferroptosis inhibition.Materials today. Bio · 2026Article
- Single-cell transcriptomics and machine learning identify RNF144B and C5AR1 as immune-related molecular signatures and therapeutic targets in myocardial infarction.Genes & genomics · 2026Article
- Identification of RUNX1 as a Biomarker for Right Ventricular Remodeling in Pulmonary Arterial Hypertension Using WGCNA.Pulmonary circulation · 2026Article
- RUNX1 is expressed in a subpopulation of dermal fibroblasts and is associated with disease severity of systemic sclerosis.Annals of the rheumatic diseases · 2026Article
- The Landscape of SERCA2 in Cardiovascular Diseases: Expression Regulation, Therapeutic Applications, and Emerging Roles.Biomolecules · 2026Review
- Fibroblast RUNX1 Induces Maladaptive Post-Myocardial Infarction Remodeling.JACC. Basic to translational science · 2026Article
- A reduced TBX5-dependent gene regulatory network links atrial fibrillation and heart failure.Nature cardiovascular research · 2026Article
- SLC31A1 knockdown mitigates post-MI heart failure via regulation of copper metabolism.Frontiers in immunology · 2026Article
- Runx1 drives cardiac fibrosis and heart failure through epigenetic activation of myofibroblasts in pressure overload-induced cardiac remodeling.BMC cardiovascular disorders · 2025Article
- A novel cardiomyopathy phenotype linked to a CHD7 missense variant.Scientific reports · 2025Article
- Identification of biomarkers associated with phagocytosis regulatory factors in coronary artery disease using machine learning and network analysis.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- A cardiac transcriptional enhancer is repurposed during regeneration to activate an anti-proliferative program.Development (Cambridge, England) · 2025Article
- KLF12 Aggravates Angiotensin II-Induced Cardiac Remodeling in Male Mice by Transcriptionally Inhibiting SMAD7.Journal of the American Heart Association · 2025Article
- Spatial integration of multi-omics single-cell data with SIMO.Nature communications · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 6 institutions in 2 countries.
Charlotte S McCarrollGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.) christopher.loughrey@glasgow.ac.uk.
Weihong HeGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Kirsty FooteDivision of Cardiovascular Medicine, Addenbrooke's Centre for Clinical Investigation, University of Cambridge, Addenbrooke's Hospital, UK (K.F.).
Ashley BradleyGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Karen McglynnGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Francesca VidlerGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Colin NixonCancer Research UK Beatson Institute, Bearsden, Glasgow, UK (C.N., K.B.).
Katrin NatherGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Caroline FattahGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Alexandra RiddellGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Peter BowmanGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Elspeth B ElliottGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Margaret BellSchool of Veterinary Medicine (M.B., E.R.C.).
Catherine HawksbyGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Scott M MacKenzieGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Liam J MorrisonDivision of Infection and Immunity, The Roslin Institute, University of Edinburgh, Easter Bush, Midlothian, UK (L.J.M.).
Anne TerryCentre for Virus Research (A.T.), University of Glasgow, Garscube Campus, UK.
Karen BlythCancer Research UK Beatson Institute, Bearsden, Glasgow, UK (C.N., K.B.).
Godfrey L SmithGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Martin W McBrideGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Thomas KubinCardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany (T.K., T.B.).
Thomas BraunCardiac Development and Remodeling, Max-Planck-Institute for Heart and Lung Research, Bad Nauheim, Germany (T.K., T.B.).
Stuart A NicklinGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
Ewan R CameronSchool of Veterinary Medicine (M.B., E.R.C.).
Christopher M LoughreyGlasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, University Place, UK (C.S.M., W.H., A.B., K.M., F.V., K.N., C.F., A.R., P.B., E.B.E., C.H., S.M.M., G.L.S., M.W.M., S.A.N., C.M.L.).
University of Glasgow · GBCancer Research UK Scotland Institute · GBCGIAR · FRMRC University of Glasgow Centre for Virus Research · GBUniversity of Cambridge · GBUniversity of Edinburgh · GB
Funding
British Heart Foundation PG/09/004/26522British Heart Foundation PG/18/9/33548Cancer Research UK C596/A17196Medical Research Council MR/K501335/1Medical Research Council MR/M021459/1
Abstract
backgroundMyocardial infarction (MI) is a leading cause of heart failure and death worldwide. Preservation of contractile function and protection against adverse changes in ventricular architecture (cardiac remodeling) are key factors to limiting progression of this condition to heart failure. Consequently, new therapeutic targets are urgently required to achieve this aim. Expression of the Runx1 transcription factor is increased in adult cardiomyocytes after MI; however, the functional role of Runx1 in the heart is unknown.
methodsTo address this question, we have generated a novel tamoxifen-inducible cardiomyocyte-specific
results
conclusionsOur data identified Runx1 as a novel therapeutic target with translational potential to counteract the effects of adverse cardiac remodeling, thereby improving survival and quality of life among patients with MI.
Indexed as
Ventricular Function, LeftVentricular RemodelingAnimalsCalcium-Binding ProteinsCalcium SignalingCells, CulturedCore Binding Factor Alpha 2 SubunitCyclic AMP-Dependent Protein KinasesDisease Models, AnimalMice, Inbred C57BLMice, KnockoutMyocardial ContractionMyocardial InfarctionMyocytes, CardiacPhospholambanPhosphorylationCalcium-Binding ProteinsCore Binding Factor Alpha 2 SubunitCyclic AMP-Dependent Protein KinasesPhospholambanRunx1 protein, mouseSarcoplasmic Reticulum Calcium-Transporting ATPasescalciumcardiac remodeling, ventricularmyocardial infarctionmyocytes, cardiacsarcoplasmic reticulum
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.